Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Stopped Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.

Conditions

• Mantle-Cell Lymphoma

Interventions

• DRUG: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan

Sponsor

Duke University

Collaborators

• [object Object]